Cognitive impairment in schizophrenia: Profile, course, and neurobiological determinants

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 433-445

  Harvey, Philip D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861142361     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00025-5     Document Type: Chapter

References (104)

1. Abi-Dargham A., Mawlawi O., Lombardo I., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002, 22:3708-3719.
2. Akil M., Pierri J.N., Whitehead R.E., et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999, 156:1580-1589.
3. Arnett P.A., Rao S.M., Grafman J., et al. Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology 1997, 11:535-544.
4. Arnold S.E., Trojanowski J.Q., Gur R.E., et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998, 55:225-232.
5. Barch D.M. The cognitive neuroscience of schizophrenia. Ann Rev Clin Psychol 2005, 1:321-353.
6. Barch D.M., Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005, 77:43-58.
7. Barch D.M., Csernansky J.G., Conturo T., et al. Working and longterm memory deficits in schizophrenia: is there a common prefrontal mechanism?. J Abnorm Psychol 2002, 111:478-494.
8. Benes F.M. Strategies for improving sensitivity of gene expression profiling: regulation of apoptosis in the limbic lobe of schizophrenics and bipolars. Prog Brain Res 2006, 158:153-172.
9. Bilder R.M., Goldman R.S., Robinson D., et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000, 157:549-559.
10. Buchsbaum M.S. Frontal lobes, basal ganglia, temporal lobes-three sites for schizophrenia. Schizophr Bull 1990, 16:377-378.
11. Buchsbaum M.S., Ingvar D.H., Kessler R., et al. Cerebral glucography with positron tomography: use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry 1982, 39:251-259.
12. Caceda R., Kinkead B., Nemeroff C.B. Involvement of neuropeptide systems in schizophrenia: human studies. Int Rev Neurobiol 2007, 78:327-376.
13. Cahn W., Rais M., Stigter F.P., et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009, 19:147-151.
14. Callicott J.H., Mattay V.S., Bertolino A., et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 1999, 9:20-26.
15. Callicott J.H., Bertolino A., Mattay V.S., et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000, 10:1078-1092.
16. Castner S.A., Williams G.V., Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000, 287:2020-2022.
17. Chen X., Sun C., Chen Q., et al. Apoptotic engulfment pathway and schizophrenia. PLoS one 2009, 4:e6875.
18. Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980, 137:383-386.
19. Davidson M., Harvey P.D., Powchick P., et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 1995, 152:197-205.
20. Davidson M., Harvey P.D., Welsh K., et al. Cognitive impairment in old-age schizophrenia: a comparative study of schizophrenia and Alzheimer's disease. Am J Psychiatry 1996, 153:1274-1279.
21. Davidson M., Reichenberg A., Rabinowitz J., et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999, 156:1328-1335.
22. Davis K.L., Kahn R.S., Ko G., et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
23. Davis K.L., Buchsbaum M.S., Shihabuddin L., et al. Ventricular enlargement in poor outcome schizophrenia. Biol Psychiatry 1998, 43:783-793.
24. Davis K.L., Stewart D.G., Friedman J.I., et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003, 60:443-456.
25. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull 2008, 34:312-321.
26. Dickinson D., Harvey P.D. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009, 35:403-414.
27. Dickinson D., Iannone V.N., Wilk C.M., et al. General and specific cognitive deficits in schizophrenia. Biol Psychiatry 2004, 55:826-833.
28. Egan M.F., Goldberg T.E., Kolachana B.S., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001, 98:6917-6922.
29. Elkis H., Friedman L., Wise A., et al. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry 1995, 52:735-746.
30. Eyler Zorrilla L.T., Heaton R.K., McAdams L.A., et al. Cross-sectional study of older outpatients with schizophrenia and healthy comparison subjects: no differences in age-related cognitive decline. Am J Psychiatry 2000, 157:1324-1326.
31. Franzen G., Ingvar D.H. Abnormal distribution of cerebral activity in chronic schizophrenia. J Psychiatr Res 1975, 12:199-214.
32. Freedman R., Hall M., Adler L.E., et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 38:22-33.
33. Friedman J., Harvey P.D., Coleman T., et al. A six year follow-up study of cognitive and functional status across the life-span in schizophrenia: a comparison with Alzheimer's disease and healthy subjects. Am J Psychiatry 2001, 158:1441-1448.
34. Friedman J.I., Tang C., Carpenter D., et al. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am J Psychiatry 2008, 165:1024-1032.
35. Garver D.L., Bissette G., Yao J.K., et al. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry 1991, 148:484-488.
36. Glahn D.C., Ragland J.D., Abramoff A., et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Map 2005, 25:60-69.
37. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000, 57:65-73.
38. Goldberg T.E., Weinberger D.R., Berman K.F., et al. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 1987, 44:1008-1014.
39. Goldberg T.E., Kleinman J.E., Daniel D.G., et al. Dementia praecox revisited. Age disorientation, mental status, and ventricular enlargement. Br J Psychiatry 1988, 153:187-190.
40. Goldberg T., Hyde T.M., Kleinman J.E., et al. Course of schizophrenia: neuropsychological evidence for static encephalopathy. Schizophr Bull 1993, 19:787-804.
41. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
42. Green M.F., Kern R.S., Braff D.L., et al. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the " right stuff?" . Schizophr Bull 2000, 26:119-136.
43. Harvey P.D., Keefe R.S.E. Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184.
44. Harvey P.D., Howanitz E., Parrella M., et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998, 155:1080-1086.
45. Harvey P.D., Silverman J.M., Mohs R.C., et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry 1999, 45:32-40.
46. Harvey P.D., Moriarty P.J., Friedman J.I., et al. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less iImpairment in reading scores compared to other skill areas. Biol Psychiatry 2000, 47:962-968.
47. Harvey P.D., Moriarty P.J., Bowie C.R., et al. Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas. J Clin Exper Neuropsychol 2002, 24:55-66.
48. Heaton R.K., Paulsen J.S., McAdams L.-A., et al. Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Arch Gen Psychiatry 1994, 51:469-476.
49. Heckers S., Rauch S.L., Goff D., et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998, 1:318-323.
50. Hirayasu Y., Shenton M.E., Salisbury D.F., et al. Hippocampal and superior temporal gyrus volume in first-episode schizophrenia. Arch Gen Psychiatry 2000, 57:618-619.
51. Holt D.J., Herman M.M., Hyde T.M., et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999, 94:21-31.
52. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008, 34:354-366.
53. Kasai K., Shenton M.E., Salisbury D.F., et al. Progressive decrease of left posterior superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003, 160:156-164.
54. Keefe R.S.E., Bilder R.M., Harvey P.D., et al. Baseline neurocognitive deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology 2006, 31:2033-2046.
55. Keshavan M.S., Tandon R., Boutros N.N., et al. Schizophrenia, " just the facts": What we know in 2008 Part 3: Neurobiology. Schizophr Res 2008, 106:89-107.
56. Kimberg D.Y., Aguirre G.K., Lease J., et al. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum Brain Map 1997, 12:246-257.
57. Kolluri N., Sun Z., Sampson A.R., et al. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005, 162:1200-1202.
58. Krystal J.H., D'Souza D.C., Mathalon D., et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003, 169:215-233.
59. Kubicki M., McCarley R., Westin C.F., et al. A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 2007, 41:15-30.
60. Kumperscak H.G., Plesnicar B.K., Zalar B., et al. Adult metachromatic leukodystrophy: a new mutation in the schizophrenia-like phenotype with early neurological signs. Psychiatr Genet 2007, 17:85-91.
61. Laruelle M. Dopamine transmission in the schizophrenic brain. Schizophrenia 2003, 365-387. Blackwell, Oxford. S.R. Hirsch, D.R. Weinberger (Eds.).
62. Lasser K., Boyd J.W., Woolhandler S., et al. Smoking and mental illness: a population based prevalence study. JAMA 2000, 284:2606-2610.
63. Lencz T., Smith C.W., McLaughlin D., et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatr 2006, 59:863-871.
64. Leonard S., Gault J., Hopkins J., et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002, 59:1085-1096.
65. Lewis D.A., Sweet R.A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest 2009, 119:706-716.
66. Matute C. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A 1998, 95:10229-10234.
67. McDonald J.W., Levine J.M., Qu Y. Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity. Neuroreport 1998, 9:2757-2762.
68. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23:315-336.
69. Mitelman S.A., Torosjan Y., Newmark R.E., et al. Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey. Schizophr Res 2007, 92:211-224.
70. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic?. Biol Psychiatry 1980, 15:283-302.
71. Nestor P.G., Shenton M.E., McCarley R.W., et al. Neuropsychological correlates of MRI temporal lobe abnormalities in schizophrenia. Am J Psychiatry 1993, 150:1849-1855.
72. Nestor P.G., Onitsuka T., Gurrera R.G., et al. Dissociable contributions of MRI volume reductions of superiortemporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 2007, 91:103-106.
73. O'Donnell B.F., Faux S.F., McCarley R.W., et al. Increased rate of p300 prolongation with age in schizophrenia: electrophysiological evidence for a neurodegenerative process. Arch Gen Psychiatry 1995, 52:544-549.
74. Olincy A., Young D.A., Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997, 42:1-5.
75. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
76. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995, 13:335-345.
77. Palmer B.W., Heaton R.K., Paulsen J.S., et al. Is it possible to be schizophrenic and neuropsychologically normal?. Neuropsychology 1997, 11:437-447.
78. Pantelis C., Velakoulis D., McGorry P.D., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
79. Paulsen J.S., Heaton R.K., Sadek J.R., et al. The nature of learning and memory impairments in schizophrenia. J Int Neuropsychol Soc 1995, 1:88-99.
80. Powchik P., Davidson M., Haroutunian V., et al. Post-mortem studies in schizophrenia. Schizophr Bull 1998, 24:325-342.
81. Purohit D.P., Perl D.P., Haroutunian V., et al. Alzheimer's disease and related neurodegenerative diseases in elderly schizophrenia patients: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 1998, 55:205-211.
82. Rapaport J.L., Addington A.M., Frangou S., et al. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
83. Rapp M.A., Schnaider-Beeri M., Purohit D.P., et al. Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. Schizophr Res 2010, 116:96-116.
84. Reichenberg A., Harvey P.D. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol Bull 2007, 133:833-858.
85. Reichenberg A., Harvey P.D., Bowie C.R., et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull 2009, 35:1022-1029.
86. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998, 24:425-435.
87. Saykin A.J., Gur R.C., Gur R.E., et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991, 48:618-624.
88. Saykin A.J., Shtasel D.L., Gur R.E., et al. Neuropsychological deficits in neuroleptic naive patients with first episode schizophrenia. Arch Gen Psychiatry 1994, 51:124-131.
89. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999, 45:17-25.
90. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995, 52:805-818.
91. Shenton M.E., Dickey C.C., Frumin M., et al. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
92. Tan H.Y., Callicott J.H., Weinberger D.R. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry 2009, 14:277-298.
93. Velakoulis D., Walterfang M., Mocellin R., et al. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry 2009, 194:298-305.
94. Verity M.A. Ca(2+)-dependent processes as mediators of neurotoxicity. Neurotoxicology 1992, 13:139-147.
95. Vita A., De Peri L., Silenzi C., et al. Brain morphology in first episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006, 82:75-88.
96. Volk D.W., Austin M.C., Pierri J.N., et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000, 57:237-245.
97. Wagner A.D., Schacter D.L., Rotte M., et al. Building memories: remembering and forgetting of verbal experiences as predicted by brain activity. Science 1998, 281:1188-1191.
98. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Ann Rev Clin Psychol 2008, 4:189-216.
99. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
100. Weinberger D.R., Torrey E.F., Neophytides A.N., et al. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1979, 36:735-739.
101. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986, 43:114-124.
102. Weiss A.P., Schacter D.L., Goff D.C., et al. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry 2003, 53:48-55.
103. Wilk C.M., Gold J.M., McMahon R.P., et al. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005, 19:778-786.
104. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008, 165:579-587.